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Abstract  
Background & Aims: Despite surgical and chemotherapeutic advances, the five-year survival rate 
for Stage IV Hepatoblastoma (HB), the predominant pediatric liver tumor, remains at 27%. YAP1 and 
β-Catenin co-activation occurs in 80% of children’s HB; however, a lack of conditional genetic 
models precludes tumor maintenance exploration. Thus, the need for a targeted therapy remains 
unmet. Given the predominance of YAP1 and β-Catenin activation in HB, we sought to evaluate 
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Approach & Results: We engineered the first conditional HB murine model using hydrodynamic 
injection to deliver transposon plasmids encoding inducible YAP1S127A, constitutive β-CateninDelN90, 
and a luciferase reporter to murine liver. Tumor regression was evaluated using bioluminescent 
imaging, and tumor landscape characterized using RNA and ATAC sequencing, and DNA foot-
printing. Here we show that YAP1S127A withdrawal mediates >90% tumor regression with survival for 
230+ days in mice. YAP1 S127A withdrawal promotes apoptosis in a subset of tumor cells and in 
remaining cells induces a cell fate switch driving therapeutic differentiation of HB tumors into Ki-67 
negative “hbHep cells” with hepatocyte-like morphology and mature hepatocyte gene expression. 
YAP1 S127A withdrawal drives formation of hbHeps by modulating liver differentiation transcription 
factor (TF) occupancy. Indeed, tumor-derived hbHeps, consistent with their reprogrammed 
transcriptional landscape, regain partial hepatocyte function and rescue liver damage in mice. 
Conclusions: YAP1S127A withdrawal, without silencing oncogenic β-Catenin, significantly regresses 
hepatoblastoma, providing the first in vivo data to support YAP1 as a therapeutic target for HB. 
YAP1S127A withdrawal alone sufficiently drives long-term regression in hepatoblastoma because it 
promotes cell death in a subset of tumor cells and modulates transcription factor occupancy to 
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Introduction 
Hepatoblastoma (HB) is the predominant primary pediatric liver cancer and most often diagnosed in 
children under five years of age. Advances in surgical resection and chemotherapy regimens have 
saved many young lives; however, the five-year survival rate remains at ~75% overall and ~27% for 
Stage IV tumors (1-3). To date, the clinical need for a HB-targeted therapeutic remains unmet. 
Yes-Associated Protein 1 (YAP1) and β-Catenin are co-activated in nearly 80% of children’s HB 
tumors (4). In mice, hepatoblastoma initiation requires oncogenic cooperation between β-Catenin 
and YAP1 (4, 5). However, it remains unclear if YAP1 is essential for HB tumor maintenance and if 
withdrawing oncogenic YAP1expression would be clinically beneficial for pediatric patients. To our 
knowledge, there are limited in vivo models to study tumor maintenance in childhood cancers, and to 
date, no conditional mouse models for HB to facilitate genetic evaluation of  oncogenic YAP1 
withdrawal.
Understanding the fate of liver cancer cells after oncogene inhibition is critical when evaluating 
targeted therapies. Previously, oncogene inhibition in cancer cells has been shown to induce 
markers of differentiation; however, these cells are thought to be dormant tumor cells, non-functional 
and prone to relapse (6-11). The reversibility of liver cancer cells remains incompletely understood, 
specifically, whether oncogene inactivation can therapeutically differentiate liver cancer cells into 
functional somatic cells that contribute to normal tissue architecture and participate in tissue 
homeostasis.
In this study, we evaluate the requirement of oncogenic YAP1 for hepatoblastoma tumor 
maintenance. We find that in established hepatoblastoma tumors withdrawal of YAP1 
overexpression without modulation of oncogenic β-Catenin activates a cell fate switch promoting a 
subset of cells to undergo apoptosis leading to regression, and the remaining tumor cells to re-
differentiate towards hepatocyte-like cells. We termed these reprogrammed cells, hepatoblastoma-
derived hepatocyte-like cells, “hbHeps.” Consistent with their hepatocyte-like transcriptional profiles, 
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Methods 
Experimental Procedures Data Accession
RNA sequencing and ATAC sequencing data herein are available for download at NCBI GEO 
GSE146548, or by reasonable request from the authors. 
ATAC Sequencing Library Preparation and Analysis 
Library Preparation
ATAC-seq was performed according to Corces et al. (2017; Supplementary Protocol 2) (12). Briefly, 
mCherry-positive hbHep cell nodules were extracted from fresh liver under a Leica MZ FL II stereo-
dissection fluorescent scope. hbHep libraries were prepared from tissue at  D33 and D64. YAP1 ON 
Tumor, YAP1 OFF D14 tumor and WT liver  libraries were prepared in biologic replicate (n=2 mice). 
Representative replicate shown in main figures. Freshly extracted liver tissue was flash-frozen, 
transported and resuspended in homogenization buffer prior to douncing. 50,000 nuclei isolated by 
gradient centrifugation were used for 30min transposition reaction. Tagmented DNA was purified 
using Zymo Clean and Concentrator-5 (Zymo D4013) and amplified with custom oligonucleotides 
listed in Buenrostro et al. 2013 Supplementary Table 1 (13). Barcoded libraries were pooled for 
paired-end sequencing on two Illumina NextSeq High-Output 150-cycle cartridges. 
ATAC-seq Pre-Analysis Processing
Demultiplexed FASTQs were trimmed by Cutadapt (13) and aligned to the mm10 reference genome 
with BWA-MEM (14). Alignments underwent PCR duplicate removal 
(https://github.com/broadinstitute/picard) and compression (15). Peaks/pileup-containing files 
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ATAC-seq Analysis
To make direct comparisons between ATAC-seq samples, each sorted, de-duplicated BAM was 
normalized using deepTools bamCoverage with 1nt bin size and CPM normalization. Coverage 
matrices depicting occupancy around enhancers and cCREs (screen.umassmed.edu) were built 
using deepTools computeMatrix (“--reference-point” mode).  BigWig correlation matrices were built 
by deepTools multiBigWigSummary with 1kb bin size and visualized by plotCorrelation, discarding 
outliers (“--removeOutliers” mode) (Fig. 6D) (16). Pairwise comparison of open enhancer regions 
(Fig. 6A-C) was conducted using Bedtools intersect (17). To minimize false-positive intersects, only 
peaks scoring >1.64 standard deviations above the corresponding sample mean (Z>1.64) were 
retained. 
Transcription Factor Footprinting
ATAC-seq output was further processed using software and instructions from the Regulatory 
Genomics Toolbox (RGT) HMM-based footprinting pipeline, HINT, available at http://regulatory-
genomics.org/ (14) . Preceding analysis, we dockerized RGT-HINT to overcome dependency 
conflicts. Transcription factor occupancy in regulatory regions was determined by matching motifs 
flanked by ATAC signal to known binding sequences in the JASPAR database (Khan et al. 2018) 
(15). Occupancy was scored and compared across samples in a pairwise manner. Line graphs for 
each motif are the default output of RGT-HINT. Z-score ranked scatterplots (Z=1.64 cutoff) were 
made by the R plot function. RGT motif “match” BED files were reformatted for use with bedtools 
intersect (steps available upon request) to isolate factor-specific binding sites. BED files were 
converted to BigBed format with bedToBigBed (Kent et al. 2010) (16) and displayed on the UMMS 
Genome Browser.
Animal Studies
All studies were performed with approval and in accordance with the University of Massachusetts 
Medical School Institutional Animal Care and Use Committee (IACUC). Mice were housed at 
University of Massachusetts Medical School Animal Facilities Core. Healthy male and female mice 
were used for studies and hydrodynamically injected at >8 weeks of age. Mouse strains purchased 
from Jax laboratories include: B6.Cg-Gt(ROSA)26Sortm1.1(CAG-rtTA3)Slowe/LdowJ 
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#001800). FAH-/- (deltaExon5) mice were a gift from Dr. Markus Grompe (Oregon Health & Science 
University). 
Results 
Conditional YAP1 cooperates with constitutive β-Catenin to drive formation of 
hepatoblastoma in vivo 
To engineer a conditional model of hepatoblastoma (HB), we used hydrodynamic injection to co-
deliver Sleeping Beauty transposon plasmids encoding human oncogenes including a TET-ON 
inducible YAP1S127A , a constitutive β-CateninDelN90 oncogene, and a luciferase reporter to the livers of 
mice transgenic for reverse tetracycline transactivator (Tg-rtTA) (Figure 1A) (17-21). The luciferase 
reporter and Sleeping Beauty transposase are encoded on the same plasmid (Figure 1A). As an 
alternative approach for tumor initiation in vivo, we co-delivered a sleeping beauty rtTA (SB-rtTA) 
plasmid with the oncogenes and luciferase plasmids into wildtype FVB mice (Figure 1A). Previous 
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liver induces hepatoblastoma (4). YAP1S127A and β-CateninDelN90 protein remain constitutively active in 
the nucleus by evading cytoplasmic retention and degradation (19, 20). Importantly, previous work 
demonstrated that hydrodynamic transposon-based expression of either YAP1S127A  or β-CateninDelN90  
alone does not induce hepatoblastoma (4).Using either transgenic Tg-rtTA or transposon SB-rtTA, 
human YAP1  oncogene overexpression can be reversibly regulated by feeding mice a diet with 
doxycycline (YAP1 ON) or without doxycycline (YAP1 OFF), allowing us to study the relevance of  
withdrawing YAP1 expression in vivo in HB tumors (Figure 1A). 
Consistent with previous work using constitutive YAP1 to establish HB in mice, in vivo cooperation 
between inducible YAP1 and constitutive β-Catenin drives the formation of large multi-focal liver 
tumors with hepatoblastoma features (Figure 1B-C, 3D). Similar to the constitutive HB model (4), the 
earliest detectable tumor by histology appeared at 4 weeks post-injection. At 6-8 weeks of ~
doxycycline treatment, mice had extensive (>30) gross surface tumors, including punctate and 
confluent lesions (Figure 1C, 3D).
By immunohistochemistry, YAP1 ON tumors were GFP-positive and express both nuclear β-
Catenin/Myc-Tag and nuclear YAP1 (Figure 1B, Supplemental Figure 1B). To functionally validate 
the conditional mouse model, we removed doxycycline to withdraw oncogenic YAP1 (i.e. YAP1 OFF, 
Figure 1A). After 3 days of (D3) doxycycline withdrawal, nuclear YAP1S127A was dramatically 
reduced in histologic sections, and virtually absent at D6 and D14 (Figure 1B, Supplemental Figure 
1A-D). The TET-ON YAP1S127A plasmid encodes a GFP reporter by an internal ribosomal entry site 
(IRES). Additionally, we found that doxycycline withdrawal also silenced expression of GFP 
downstream of YAP1 by D14 (Figure 1A, Supplemental Figure 1A, 1E).
The expression of YAP1 and its target gene, Ctgf, were significantly reduced in day 14 to 21 (D14-
21) YAP1 OFF tumors  demonstrating that the inducible YAP1 oncogene is rapidly inactivated 
(Figure  1B,D). Concordantly, α-fetoprotein (Afp) and Glypican C3 (Gpc3), stem-like clinical and 
prognostic markers of HB, are also reduced significantly in YAP1 OFF D14-21 tumors (Figure 1E) 
(22).
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To characterize the transcriptional landscape associated with YAP1 withdrawal, we compared the 
mRNA profiles of YAP1 ON and YAP1 OFF D6 early regressing tumors (Figure 2A-B, 
Supplemental Table 1). Consistent with the rapid inactivation of YAP1, many canonical YAP1 target 
genes, including Birc5 (Survivin), Amotl2, and Foxm1, were reduced in YAP1 OFF D6 tumors 
(Figure 2C-E). In addition, six days of YAP1 withdrawal suffices to downregulate many tumor-
associated signatures, including proliferation signatures (Hallmark G2M checkpoint, Mitotic Spindle, 
E2F targets) (Figure 2F, J-L).
Previous studies showed that YAP1 can co-regulate β-Catenin target gene expression in vitro (4). 
We observed that YAP1 withdrawal alone, without modulation of oncogenic β-Catenin, 
downregulates two canonical β-Catenin target genes, Myc and CyclinD1 (Figure 2F-G). Gene set 
enrichment analysis (GSEA) further suggests downregulation of Myc targets 
(Hallmark_Myc_TargetsV1) in YAP1 OFF D6 early regressing tumors (Figure 2L). Thus, YAP1 
withdrawal may partially abrogate the oncogenicity of β-Catenin through downregulation of its target 
genes. 
Conditional murine hepatoblastoma gene expression mimics the poor prognosis C2 HB 
pediatric 
subtype 
Differentiation status impacts HB prognosis. Indeed, Cairo et al. first characterized children’s 
hepatoblastoma tumors as either well-differentiated human pediatric hepatoblastoma Class 1 (C1) 
tumors with favorable outcomes, or as undifferentiated highly proliferative Class 2 (C2) tumors with 
poor prognosis (23). C1 and C2 tumors have comparable rates of Wnt pathway mutations, 
suggesting β-Catenin alone does not determine the aggressiveness of HB tumors. Indeed, unlike C1 
tumors, poor prognosis C2 tumors differentially activate YAP1, express YAP1 target genes, and have 
high levels of proliferation and stem markers (23, 24). 
To characterize the subtype of hepatoblastoma recapitulated in our conditional YAP1 ON model, we 
returned to the  RNA-sequencing of YAP1 ON tumors and YAP1 OFF D6 regressing tumors (Figure 
2A-B). Using GSEA, we found that six days of YAP1 withdrawal was sufficient to downregulate 
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enriched for GSEA signatures Cairo Hepatoblastoma Classes Down, Cairo Hepatoblastoma Down, 
and Cairo Liver Development Down (Figure 2M-O). The Cairo Hepatoblastoma Classes Down 
predefined gene signature uses genes downregulated in invasive C2 tumors compared to favorable 
C1 tumors. Similarly, the Cairo Hepatoblastoma Down signature uses genes downregulated in all HB 
tumors compared to normal liver. Thus, YAP1 OFF D6 tumors downregulate C2 associated genes, 
and upregulate genes associated with C1 tumors and normal liver. 
To further characterize our conditional murine HB as congruent with a  well-differentiated favorable 
C1 or a poor prognosis C2 tumor subtypes, we performed Ingenuity Pathway Analysis (IPA) 
comparing YAP1 ON/YAP1 OFF D6 gene expression to C2/C1 human hepatoblastoma microarray 
from Cairo et al. (23). Similarly, to our YAP1 ON and YAP1 OFF mouse tumors, C1 and C2 human 
tumors have comparable Wnt activation, but C2 tumors have differential YAP1 activation (23-25). 
Like GSEA, IPA  analyses allows for comparison analyses of curated gene signatures. IPA revealed 
that top Upstream Gene Pathways I, Canonical Pathways, and Disease/function IPA signatures were 
congruent between YAP1 ON/OFF D6 mouse HB tumors and C2/C1 human HB tumors (26) (Figure 
1F-H). Indeed, we observe upregulation of proliferation and cell survival, and downregulation of liver 
metabolism and cell death signatures in 
C2 human and YAP1 ON mouse tumors. 
C2 tumors can be further stratified into the Hooks highly aggressive C2A and intermediate C2B 
subtypes (24, 25). Analyzing the Hooks signature (25), we found that YAP1 ON tumors closely mimic 
the aggressive C2A  tumors that express high levels of Top2A, and reduced levels of differentiation 
maker HSD17B6 (compared to WT FVB mice; Figure 2I) and YAPOFF D6 tumors more closely 
resemble C1 tumors (Figure 2P), suggesting that YAP1 status determines tumor aggressiveness. 
YAP1 ON tumors also display some features of moderately aggressive C2B tumors, i.e. their 
increased levels of vimentin. 
Taken together, these analyses suggest that YAP1 ON in conditional murine hepatoblastoma drives 
an aggressive phenotype consistent with the “C2” subgroup of pediatric tumors. Moreover, 
withdrawal of YAP1 alone—i.e. without silencing oncogenic β-Catenin—suffices to modulate the 
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Withdrawal of oncogenic YAP1 alone mediates >90% tumor regression 
Using the luciferase reporter, we then serially monitored tumor progression over time in live mice 
using in vivo bioluminescent imaging. We found that YAP1 OFF tumors gradually regressed, and by 
9 weeks luminescent signal was reduced 93% ± 6% (n=3; Figure 3A-B). Moreover, histological 
examination revealed ~10-fold fewer Ki67-positive proliferating cells in regressing YAP1 OFF D6-14 
tumors than in YAP1 ON tumors (YAP1 ON, 242.5 ± 53.9 vs. YAP1 OFF, 26.8 ± 8.7 positive cells per 
20× field; n=3) and a slight increase in cleaved caspase 3-positive apoptotic cells (YAP1 ON 0.416 ± 
0.51 vs. YAP1 OFF 9.33 ± 8.75 positive cells per 20× field; n=3; Figure 3C, 4B, and Supplemental 
Figure 2A-B). These results indicate that genetic withdrawal of YAP1 can regress hepatoblastoma 
driven by oncogenic YAP1 and β-Catenin.
YAP1 withdrawal results in durable tumor regression for >230 days
We observed ~93% regression of HB tumors in YAP1 OFF livers by week 7, and no evidence of 
further regression or tumor relapse in weeks 8 or 9 (Figure 3A-B), suggesting that tumor regression 
might be stable. After 10 weeks of YAP1 withdrawal (YAP1 OFF Day 70 (D70+), macroscopic 
examination of livers revealed no evidence of surface tumors (n=3; Figure 3D). Moreover, liver 
histology revealed lack of obvious tumor nodules (Figure 3E), and proliferating Ki67-positive cells 
were virtually absent from YAP1 OFF D70+ livers (3.75 ± 2.83 positive cells per 20X field, n=3; 
Figure 4B and Supplemental Figure 3A) compared to YAP1 ON tumors. 
To evaluate long-term survival of YAP1 OFF mice, we allowed a cohort of mice to proceed with 
sustained YAP1 withdrawal (Figure 4A). Whereas YAP1 ON mice reached a lethal burden of tumors 
by 65.6 days on average post tumor initiation (n=8), YAP1 OFF mice were viable 230 days after 
YAP1 OFF (n=2), and low levels of luciferase signal persisted in YAP1 OFF livers as mice aged 
(Figure 4A and Supplemental Figure 3B). Thus, sustained YAP1 withdrawal alone, without 
inactivation of oncogenic β-Catenin, in this HB mouse model sufficiently drives durable tumor 
regression, providing long-term survival benefit. 
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The persistent luminescence in YAP1 OFF D230+ livers suggested that, although tumors were 
significantly regressed, YAP1 OFF livers retain residual cells of tumor lineage. Indeed, staining YAP1 
OFF D70+ livers for the Myc-tag fused to oncogenic β-Catenin (Figure 1A) revealed regions of Myc-
tag-positive cells with hepatocyte morphology (13 ± 9.9 residual nodules per liver section, n=4 mice; 
Figure 4C-D). Further, reintroducing doxycycline to the diet after tumor regression induced tumor 
growth (Supplemental Figure 4A-C). Nevertheless, with sustained YAP1 withdrawal, residual tumor 
lineage cells remain camouflaged within the liver (Figure 4C-D).  Because they are morphologically 
similar to normal hepatocytes, we have termed these residual tumor lineage cells “hepatoblastoma-
derived hepatocyte-like cells” (hbHep cells).
YAP1 withdrawal induces therapeutic differentiation of HB tumor cells
In our RNA-Seq analysis of early regressing YAP1 OFF D6 tumors (Figure 2), the top 10 
upregulated GSEA hallmark pathways included multiple liver metabolic pathways associated with 
normal hepatocyte function, such as xenobiotic and fatty acid metabolism pathways suggesting that 
YAP1 withdrawal induces mature hepatocyte gene expression in HB tumors (Figure 5A-C and 
Supplemental Figure 5A,D, Supplementary Table 1).Consistent with the hepatocyte-like 
morphology of hbHeps, we hypothesized that YAP1 withdrawal activated a cell fate switch driving 
differentiation of HB tumor cells towards mature hepatocytes. 
It has been previously shown that YAP1 and differentiation signaling are often polarized in the liver 
(27-32). Indeed, GSEA analysis shows target genes of Hnf4α and Foxa2—transcription factors that 
promote hepatocyte differentiation (28, 33, 34)—were both upregulated in YAP1 OFF tumors (Fig 5D 
and Supplemental Figure 5B). Further, immunohistochemistry revealed the presence of nuclear 
HNF4α and FoxA2 in YAP1 OFF D6 tumors but not in YAP1 ON tumors (Figure 5I). Concordantly, in 
both human pediatric HB microarray (23) and human hepatocellular carcinoma TCGA datasets (35), 
the YAP1 target gene CTGF and HNF4α/FOXA2 are inversely correlated, indicating the general role 
of YAP1 in suppressing differentiation in human liver cancer (Figure 5E-H). 
We further explored this phenomenon in human hepatoblastoma cells. We used CRISPR/Cas9 to 
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and which possess a mutation in CTNNB1 and express nuclear YAP1 (4, 36). Following YAP1 
knockout, we observed an increase in canonical liver markers, including ApoA2, Ces3, Cyp2A6, 
Cyp2e1, Cyp3A5, and OAT (Supplemental Figure 5E-F), suggesting a more differentiated state.
Further, the top 5 genes upregulated in YAP1 OFF D6 tumors belong to the family of major urinary 
proteins (Mups) (Figure 5A and Supplemental Figure 5C, Supplemental Table 1). Mup proteins 
serve as a marker of mature hepatocytes (37, 38). Immunofluorescence detected virtually no Mup 
expression in YAP1 ON tumors, and partially restored levels of Mup in hbHep cells compared to 
adjacent normal hepatocytes in YAP1 OFF D70+ livers (Figure 5J). These findings further support 
YAP1 withdrawal promoting induction of mature hepatocyte gene expression in HB tumor cells.  
YAP1 withdrawal promotes remodeling of the chromatin landscape in HB tumor cells  
We hypothesized that YAP1 withdrawal drives transcriptional reprogramming for upregulation of 
mature hepatocyte gene expression, and the subsequent generation of hbHep cells, in part through 
modulation of liver chromatin accessibility. It has been previously demonstrated that YAP1 can exert 
transcriptional control through regulation of chromatin structure, specifically enhancer regions (39, 
40). To assess open chromatin structure, we performed Assay for Transposase-Accessible 
Chromatin using sequencing (ATAC-seq) (12) in YAP1 ON, YAP1 OFF D14 tumors, hbHep cells 
(D33 and D64) and normal liver. We isolated hbHep cells by fluorescently labeling them with 
mCherry upstream of TET-ON YAP1S127A (Supplemental Figure 6A). Using a Leica MZ FL II stereo-
dissection fluorescent scope, mCherry-positive hbHep cell nodules were extracted using 
fluorescence. Further, using mCherry as a lineage tracing marker, we confirmed that the mCherry+ 
area in the YAP1 OFF livers were of the tumor lineage (Supplemental Figure 6B-C). Grossly and 
histologically, mCherry+ hbHep cells were similar in appearance to WT liver. 
By analyzing intersected ATAC-seq peaks between YAP1 ON, YAP1 OFF D14 regressing tumors, 
hbHep cells, and WT liver, we observed that hbHep cells share a higher percent of intersected ATAC 
peaks and enhancers with WT liver than with YAP1 ON (Figure 6A-C and Supplemental Figure 
6D-G). Next, we performed hierarchical clustering for total peaks. Two hbHep samples and WT Liver 
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When we examined enhancer occupancy in biological replicates of YAP1 ON tumor, YAP1 OFF D14, 
and WT liver, we found decreasing occupancy in YAP1 OFF D14 livers at adult and embryonic 
enhancers (Supplemental Figure 7). Interestingly, when we examined embryonic enhancer 
occupancy for hbHeps, we observe a transient increase in enhancer occupancy at the D33 timepoint 
compared to the later D64 hbHeps. We suspect this transient increase reflects the dynamic 
chromatin remodeling and unique transcription profile that we observe in early hbHeps; however, 
further detailed investigation will be required to define the genomic transitions that accompany the 
adoption of the hbHep cell fate (Supplemental Figure 8).  
Finally, if we look at individual ATAC-seq tracks, we observe the YAP1 OFF D6 RNA-seq 
upregulated gene and mature hepatocyte marker, Mup9, has differential peaks in hbHeps and WT 
liver compared to YAP1 ON tumor (Figure 6E). 
YAP1 withdrawal modulates liver transcription factor occupancy promoting the generation of 
hbHep cells 
Finally, to understand more clearly how YAP1 withdrawal  promoted differentiation of HB tumor cells 
to hbHeps, we performed computational DNA footprinting in regulatory regions in our ATAC-seq 
dataset. As expected, we observe decreased occupancy at Tead and Fos-Jun motifs in YAP1 OFF 
D33 hbHeps compared to YAP1 ON tumors (Fig 6F and Supplemental Figure 9A-D, 
Supplemental Table 2). Further in YAP1 OFF D33 hbHeps, we observe increased occupancy at the 
motif of Retinoid X receptor alpha (Rxra), known to mediate xenobiotic CYP450 expression, and 
multiple canonical liver differentiation transcription factors belonging to the Hnf and FoxA families, 
including Hnf4α, Hnf1α, Hnf1B, Onecut1, Onecut3, FoxA1, and FoxA2 (Figure 6G and 
Supplemental Figure 10A-D, Supplemental Table 3). These data indicate that YAP1 withdrawal 
drives transcriptional reprogramming and differentiation of HB tumor cells into hbHeps by modulating 
occupancy of canonical liver differentiation transcription factors to promote mature hepatocyte gene 
expression (Figure 6H). 
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Oncogene withdrawal in mouse models of adult liver cancer has been shown to induce features of 
hepatocyte differentiation, but it remains unknown if the differentiated tumor cells are functional in a 
tissue context in vivo (8, 41). To determine if hbHep cells have somatic hepatocyte function in vivo, 
we assayed their ability to rescue liver damage in a mouse model of tyrosinemia. Fah–/– mice 
(deficient for the fumarylacetoacetate enzyme) fail to fully metabolize tyrosine and accumulate toxic 
metabolites that cause liver damage, weight loss, and death. Fah deficiency can be rescued by 
NTBC (supplied in water), which blocks the buildup of toxic metabolites (42-44), or by repopulating 
the liver with Fah-positive hepatocytes following NTBC withdrawal (42, 44-47). The proliferation of 
Fah-positive hepatocytes restores the functional/metabolic capacity of the liver rescuing the weight 
loss phenotype. If the liver is repopulated by Fah-positive cells that lack expression of critical liver 
metabolic enzymes, the weight loss phenotype will not be rescued.
We engineered a dual-function transposon plasmid that encodes a constitutively expressed Fah 
gene and TET-ON inducible YAP1S127A (YAP1-Fah; Figure 7A,B). We delivered YAP1-Fah, β-
CateninDelN90, and SB-rtTA plasmids to Fah–/– mice by hydrodynamic injection and fed mice with 
doxycycline to induce YAP1 expression and HB tumor formation. Once tumors were established, we 
removed doxycycline and allowed tumors to regress (Figure 7A). We then withdrew NTBC from the 
water supply to induce liver damage and monitored mice for 10% total body weight loss. 
Untreated Fah–/– control mice rapidly lost 10% of their total body weight and needed to be euthanized 
within 10 days, with a median of 2.5 days. Unlike Fah–/– control mice, Fah-positive hbHeps 
maintained weight out to 23 days, with median weight maintenance of 13 days (Figure 7C). 
Immunohistochemistry revealed that livers harbor hbHep cells positive for Myc-tagged β-Catenin and 
the Fah enzyme (Figure 7D-E). Whereas Fah-negative liver (in the control mice and in tissue 
adjacent to hbHep regions) showed abundant cell death, the Fah-positive hbHep areas of the liver 
appeared healthy (Figure 7E). 
To promote expansion and recovery of hbHep cells into the damaged Fah–/– liver, Fah-positive 
hbHep mice were fed NTBC until normal weight was restored. NTBC was then removed, and mice 
were monitored for weight loss. When mice lost 10% of their body weight, NTBC was provided at 
least 2X to promote hbHep expansion (n=3) (Figure 7H). Fah-positive hbHep mice maintained 
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needed to be provided (Figure 7H). By contrast, untreated Fah–/– control mice rapidly lost 10% of 
their total body weight required euthanasia between 2.5 and 10 days (Figure 7C). 
On immunohistochemical examination, D114+ liver sections were grossly positive for Fah and the 
Myc epitope (n=3 mice, D114+) (Figure 7G). Myc-positive and Fah-positive nodular areas overlap in 
serial sections of liver, allowing hbHep cells to be tracked easily (Figure 7I-J). Gross examination of 
the liver under a dissection scope revealed 2 to 3 GFP-positive lesions per mouse (data not shown). 
GFP-positive tumors are presumed to be TET-ON escaper nodules. No other gross or histologic 
abnormalities were noted in the D114+ hbHep mice. 
 
To further investigate the gene expression profile of hbHeps, we performed RNA-sequencing 
analysis in the three D114+ hbHep mice compared to Fah–/– mice on NTBC. Control Fah–/– mice on 
NTBC do not accumulate toxic metabolites, and therefore maintain healthy hepatocytes and normal 
hepatocyte gene expression. Gene expression comparisons between YAP1 ON, YAP1 OFF D6 
regressing tumors, Fah-positive D114+ hbHeps, and NTBC-fed Fah–/– mice  suggest that YAP1 
withdrawal results in a gradual progression over time toward normal hepatocyte function 
(Supplemental Figure 11, Supplemental Table 6-8).
Specifically, Ingenuity Pathway Analysis (IPA) revealed a loss of Disease and Function liver cancer 
signatures (Liver Cancer, Liver Tumor, Liver Carcinoma) in hbHeps compared to YAP1 ON tumors 
(Supplemental Figure 11A, Supplemental Table 7). Further, hbHeps and WT liver also trend 
together on Hnf4α and Myc IPA Upstream Regulator signatures (Supplemental Table 6). Indeed, 
examining scaled reads per base (i.e., normalized transcript count), we observed comparable levels 
of Myc expression between YAP1 OFF D6 tumors, D114+ hbHeps, and WT liver (Supplemental 
Figure 11G). This finding suggests that YAP1 withdrawal sufficiently dampens the hepatoblastoma 
MYC signature observed in children’s aggressive hepatoblastoma tumors.  
Besides loss of tumorigenic signaling in hbHeps, we also observed restoration of some hepatocyte 
metabolic function. We observe comparable scores for hbHeps and WT liver in liver-specific IPA 
Canonical Pathways, including PXR/RXR Activation, Xenobiotic Metabolism, Oxidative 
Phosphorylation, and Super-pathway of Cholesterol Biosynthesis (Supplemental Tables 6-8). 
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expression of Mups, the mature hepatocyte marker (Supplemental Figure 11B,D-F). This finding is 
consistent with the immunofluorescence in hbHeps of Mup family proteins (Figure 5J). We observe 
increased levels of Mups in hbHeps compared to tumor, but the level is not fully comparable to WT 
liver. Finally, using the Hooks Four-Gene Signature, whereas YAP1 ON tumors resemble C2 tumors 
and YAP1 OFF D6 tumors resemble C1 tumors, hbHeps more closely resemble WT liver 
(Supplemental Figure 11C). 
Thus, hbHep cells engineered to express Fah can rescue liver function in Fah-deficient mice, 
demonstrating that the transcriptionally reprogrammed hbHeps resemble functional hepatocytes that 
can repair liver damage. 
Discussion 
Using a conditional mouse model of the aggressive C2 subtype of pediatric HB, we have shown that  
sustained withdrawal of YAP1 results in >90% tumor regression, demonstrating that HB tumor 
maintenance requires YAP1. Though driven by both β-Catenin and YAP1, HB is sensitive to the 
inactivation of YAP1 alone, perhaps because YAP1 inactivation also dampens β-Catenin signaling in 
this model (4).   Despite the persistence of residual tumor-lineage cells, sustained YAP withdrawal 
mediates durable tumor regression and long-term survival. These results provide preclinical evidence 
in favor of evaluating YAP1-targeted therapies, either alone or in combination with other agents, in 
the treatment of HB. Moreover, the >90% tumor regression suggests that YAP1 inhibition may 
benefit children as a neoadjuvant therapy to improve the resection of HB tumors, or as a post-
resection adjuvant therapy to promote regression of residual disease. Further investigation is needed 
to understand how human hepatoblastoma will respond to pharmacologic inhibition of oncogenic 
YAP1. Nevertheless, YAP1 inhibition presents a potentially tractable therapeutic strategy in children 
with HB. 
We propose that withdrawal of YAP1 overexpression in hepatoblastoma tumor cells activates a cell 
fate switch that promotes apoptosis and, in a subset of tumor cells, differentiation (Figure 6H). In our 
system, sustained YAP1 rehabilitates a subset of tumor cells into a hepatocyte-like state, hbHep 
cells, that can rescue liver damage. While oncogene inactivation has been shown to induce features 
of differentiation, if the differentiated tumor cells are functional in a tissue context in vivo remained 
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switch allowing HB tumor cells to reprogram and differentiate toward a functional hepatocyte-like 
state that can rescue liver damage. 
This work provides clear functional evidence that hepatoblastoma cells can be therapeutically 
differentiated to mimic a normal somatic cell state, offering a new outcome in the traditional paradigm 
of oncogene addiction and inactivation. Future work will determine how HB cells choose the fate 
between cell death and differentiation and which signals maintain the survival of hbHep cells. Our 
work supports YAP1 inhibition as a rational targeted therapeutic for the treatment of hepatoblastoma 
and provides a new in vivo model to explore cell fate decisions as tumor cells are therapeutically 
differentiated into a functional somatic-like state. 
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Figure Legends  
 
Figure 1. Conditional murine hepatoblastoma gene expression mimics the poor prognosis C2 subtype 
of human hepatoblastoma (HB).  
(A) Sleeping Beauty transposon plasmids are hydrodynamically injected into the liver of transgenic rtTA mice 
(Tg-rtTA). TREt encodes a TET-ON promoter, IR marks inverted repeats. Alternatively, rtTA was co-delivered 
with sleeping beauty plasmids to FVB mice by hydrodynamic injection (SB-rtTA). (B) Top: Representative H&E 
(10X lens), scale bars 75 µm and IHC in YAP1 ON tumors (20X lens), n=3 mice, scale bars 100 µm. Bottom: 
Representative H&E (10X lens), scale bars 75 µm and IHC in YAP1 OFF D6 tumors (20X lens), n=3 mice, scale 
bars 100 µm) (C) Representative gross live tumor image in YAP1 ON SB-rtTA mouse (D) qPCR YAP1, Ctgf in 
YAP1 ON and YAP1 OFF D14-21, n=3 tumors per mouse, p <0.0001 unpaired t-test, n=3 mice. (E) qPCR of 
clinical HB marker Afp and Gpc3 in YAP1 ON and YAP1 OFF D14-21, n=3 tumors per mouse, p <0.02, p<0.0001, 
respectively, unpaired t-test, n=3 mice. (F-H) Mouse HB (mHB) gene signatures resemble human HB (hHB). IPA 
ingenuity analysis comparing YAP1 ON/OFF mouse HB to C2-poor/C1-favorable prognosis human HB 
microarray data from Cairo et al. Top 10 IPA Upstream Gene pathways I, Canonical Pathways, Disease/function 
signature pathways respectively  
 
Figure 2.  YAP1 withdrawal reprograms gene expression in murine hepatoblastoma.  
(A) Heatmap of differentially expressed transcripts log2fold change in YAP1 OFF D6 tumors compared to YAP1 
ON tumors, n=4 tumors per group, genes shown in heatmap >2 upregulated or <0.5 down-regulated fold change, 
Student’s t-test, p<0.01, Full fold change gene list shown in Supplemental Table 1. (B) Volcano plot of 
differentially expressed genes in YAP1 OFF D6/YAP1 ON tumors, genes with log2fold >1 and <-1 shown, p<0.05. 
(C-H) TPM RNA-seq counts in YAP1 ON and YAP1 OFF D6 tumors, n=4 tumors per group, unpaired t-test. (I) 
Top 10 most downregulated Gene Set Enrichment Analysis (GSEA) Hallmark pathways in YAP1 OFF D6/ YAP1 
ON tumors. (J-O) GSEA analysis in YAP1 OFF D6/ YAP1 ON tumors, FDR q-value <0.0001 (P) Hooks Four 
gene signature for C2 poor prognosis and C1 favorable prognosis tumors in YAP1 ON and YAP1 OFF D6 tumors 
gene expression, n=4, control FVB liver shown for WT 
 
Figure 3. YAP1 withdrawal results in >90% tumor regression in a conditional mouse model of 
hepatoblastoma. 
(A) Representative Luciferase imaging shows YAP1 OFF tumor regression, n=3 mice (B) Quantification of a. 
Mean relative luciferase; error bars are SEM, n=3 mice. (C) Cleaved caspase 3 (CC3) positive cells in YAP1 ON 
and YAP1 OFF D3-14 tumors, n=4 20X sections per mouse, n=3 mice. (D) 10 weeks YAP1 OFF livers do not 
harbor macroscopic surface tumors compared to YAP1 ON. Representative liver images, YAP1 ON SB-rtTA 
mouse and YAP1 OFF Tg-rtTA mice.  (E) Paired histology from Panel D, YAP1 ON  SB-rtTA mouse and YAP1 
OFF Tg-rtTA mice are shown, scale bars 100 µm.  
 
Figure 4. Sustained YAP1 withdrawal results in durable tumor regression and generates non-proliferative 
tumor lineage cells with hepatocyte morphology.  
(A) Long-term tumor regression in YAP1 OFF mice. Residual luminescent signal persists in YAP1 OFF mice 
(SB-rtTA plasmid) 231 days post-doxycycline withdrawal, n=2 mice. (B) Ki67+ cells per 20X field, n=4 20X 
sections per mouse, n=3 mice. One-Way Anova with Tukey multiple comparisons test. (C-D) Myc-tag IHC 
detects residual cells of tumor lineage (circled area) with hepatocyte morphology in YAP1 OFF mice (n=4). We 
termed these cells hepatoblastoma-derived hepatocyte-like cells (hbHep). Scale bars are 100µm, YAP1 ON 
tumor H&E serves as a control. IHC and H&E shown are serial sections. 
 
Figure 5.  YAP1 withdrawal promotes hepatocyte differentiation in mouse hepatoblastoma.  
(A) 20 most significant upregulated genes in YAP1 OFF tumor RNA-Seq include major urinary proteins (Mups), 
cytochrome p450 enzymes, and other metabolic liver enzymes, p<0.05 (B) Top GSEA signatures. (C-D) 
Representative GSEA Signatures. (E-F) Inverse correlation between YAP1 target gene CTGF and differentiation 
markers in human hepatoblastoma microarray data (n=25) from Cairo et al, Spearman’s Correlation analysis. 
(G-H) Inverse correlation between YAP1 target gene CTGF and differentiation markers in human hepatocellular 
carcinoma TCGA data (n=348) from Uhlen at al, Spearman’s Correlation analysis. (I) YAP1 OFF induces 
hepatocyte differentiation factors FoxA2 and Hnf4α. Representative immunohistochemistry in YAP1 OFF D6 
compared to YAP1 ON, scale bars 25 µm. (J) Hepatocyte marker MUP is partially restored in long-term YAP1 
OFF D70 hbHep cells compared to YAP1 ON tumors, scale bars 100 µm. Representative immunofluorescence 
shown.  
 
Figure 6. Induction of mature hepatocyte gene expression in hbHep cells results from YAP1 modulation 
of liver differentiation transcription factor occupancy  
(A) ATAC peak intersects shared with WT liver in YAP1 ON, YAP1 OFF D14 regressing tumor, and hbHeps 
YAP1 OFF D33 and D64. Representative ATAC peaks from one representative sequencing replicate for YAP1 
ON, YAP1 OFF D14 and WT liver sequencing experiment shown for Figure 6. (B-C) Total ATAC peak intersects 
between hbHeps D64 and WT liver, WT liver and YAP1 ON tumor. Not to scale. (D) Spearman correlation values 
with hierarchical clustering YAP1 ON, YAP1 OFF D14, hbHeps D33 and D64 (E) Representative genome 
browser ATAC tracks for Mup9, gene found to be highly upregulated in RNA-seq YAP1 OFF D6/YAP1 ON, (F-
G) DNA Footprinting analysis of ATAC Seq YAP1 OFF hbHeps D33 shows decreased occupancy at Tead1 motif 
(F) and increased occupancy at Rxra motif compared to YAP1 ON tumors (H) Model: YAP1 ON mouse tumors 
resemble aggressive C2 human tumors. YAP1 withdrawal promotes downregulation of Myc, Cyclin D1, and HB 
prognostic markers promoting a C1-like favorable prognosis tumor. Long-term YAP1 withdrawal promotes 
durable tumor regression by promoting apoptosis in a subset of tumor cells, and differentiation towards a 
hepatocyte-like state in other tumor cells, i.e. “hbHeps.”  
 
Figure 7.  Hepatoblastoma-derived hepatocyte-like cells (hbHep cells) rescue liver damage in Fah mutant 
mice. (A) Experimental Design. A dual function transposon plasmid encodes a constitutive Fah gene and TET-
ON inducible YAP1 (termed YAP1-Fah plasmid). The plasmid combination was injected in Fah-/- mice to model 
HB tumor induction and regression. Only hbHep cells, but not host liver hepatocytes, express the Fah enzyme. 
(B) Validation of YAP1-Fah plasmid. Western blot in HCT116 cells transfected with indicated plasmids. (C) 
Kaplan Meier curve of hbHep expressing Fah (n=8) compared to untreated control Fah-/- mice (n=6) following 
NTBC withdrawal. Number of days until 10% body weight loss is shown, p<0.002, Log-rank (Mantel-Cox) test. 
(D) hbHep mice post NTBC withdrawal harbor Myc-tag positive hbHep cells. Representative 
immunohistochemistry in control Fah-/- mice and hbHep mice, n=3, scale bars 100 µm (5X lens). (E) The Myc 
tag positive hbHep cells are also positive for Fah. Representative immunohistochemistry (20X lens) in Fah-/- 
mice and hbHep mice (n=3). WT liver H&E is for comparison, scale bars 100 µm. The hbHep group shows serial 
liver sections of the white square region from panel d. White line denotes the border between hbHep area and 
host liver. Arrows denote dead hepatocytes in the Fah-/- liver area. (F) Representative WT liver (G) 
Representative immunohistochemistry (20X) lens in hbHep mice D117 (n=3 mice), white box from Panel I and J 
(H) Representative weight trace in hbHep mouse, blue marks NTBC cycling, (n=3 mice) (I-J) Scan of liver slice, 
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q value = 3.86e-6
R= -0.268
q value = 2.87e-6
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